Abstract Learning Objectives After completing this course, the reader will be able to: List the
advantages of combination chemotherapy and radiotherapy. Explain the rationale for doing …

Gemcitabine is a potent radiosensitizer of human tumor cells. This review summarizes our
preclinical and early clinical studies designed to elucidate the mechanism of action of …

Gemcitabine is a nucleoside analogue with excellent clinical activity against solid tumors.
Within the cell, gemcitabine is rapidly phosphorylated to its active di-and triphosphate …

SEVERAL YEARS AGO, the late Gerry Grindey had the foresight to put in place at Eli-Lilly
Ltd a focused program of new drug discovery based on novel mechanisms of action and …

In the last three decades, gemcitabine has progressed from the status of a laboratory
cytotoxic drug to a standard clinical chemotherapeutic agent and a potent radiation …

Gemcitabine is a novel nucleoside analog with demonstrated efficacy across a range of
solid tumors. This paper reviews the single-agent safety profiles of 979 patients in 22 …

Gemcitabine is a potent radiosensitizer in both laboratory studies and in the clinic. Initial
laboratory studies showed that gemcitabine radiosensitizes a wide variety of rodent and …

Gemcitabine2 is a pyrimidine analogue of deoxycytidine with a wide range of antitumor
activity against solid tumors (1). In particular, it has shown promising results as a single …

PURPOSE: The mechanism of radiosensitization by gemcitabine is still unclear. It has been
hypothesized that the accumulation of cells in early S phase may play a role in enhancing …

Abstract Gemcitabine, 2′ 2′-difluoro-2′-deoxycytidine, is an inhibitor of DNA synthesis
and has been shown previously in vitro and in vivo to enhance the cytotoxic activity of …